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~-'4"- I  Low Level Physical Training Improves Oxygen Peak 
Consumption in Patients With Congestive Heart 
Failure Despite Long Term Beta Adrenergic 
Blockade by Enhancing Vascular Conductance and 
Growth 
Laura Demopeufos, Marco Testa. Gemrdo Zullo, Marco Gentilucci, 
Margaret Jones, Michael Yeh, Pugazhendhi Vijdyaraman, Patrick Moore, 
Thlerry H. LeJemtel. Albert Einstein College of Medicine, Bronx, Ne~ York 
In the absence of beta adranergic blockade (BAG), 12 weeks of low level 
physical training (PT) at a workload corresponding to _<50% of peak oxy- 
gen consumption (VO2) has been shown to increase peak VO2 in patients 
with congestive heart failure (CHF). In normal subjects, BAB aten uates the 
benefits of PT by preventing cardiac and skeletal muscle adaptations that 
contribute Io increasing maximum VO2. Accordingly, 10 patient~ with CHF on 
long term therapy with ACE tnhibifors, digexin, loop diuretics, : . BAB (rest 
and peak heart rates 64/rain and t18/min) unde,,went 12 weeks of low level 
PT. Peak VO2 (mltmin/kg) and calf peak hypemmic response by ptethys- 
mograpby (CPHR, ml/min/100 ml) were measured at baseline (BL) and after 
12 weeks of low level PT. Gene expression of vascular endothelial growth 
factor (VEGF) was quantified by competitive PCR or~ reverse transcnbed 
mRNA obtained from vestus latemlis muscle biopsies at BL and 12 weeks. 
VEGF was normalized to glyceraldohyde-3-phesphalq dehydrugenase, and 
expressed a.~ a fold increase from BL. 
Peak VO2 CPHR VEGF 
BL 13.8 18.4 - 
12 weeks 17.4" 26.3* 3--7 
• p < 0.0=; vs BL 
Conclusion: In patients with CHF on long term BAB, low level PT sub- 
stantially increases 1) peak VO2. 2) CPHR and gene expression of VEGR 
Enhanced vasodilatory capacity and angiogenesi~, in the skeletal muscle 
beds appear to mediate the improvement inpeak VO2 induced by low level 
PT in these patients. 
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-5~ Amledarone Produces Effects Similar to ~-Blockers 
in CHF 
Barry M. Massie, Susan G. Fisher, Martha Radford, Ross D. Fletcher, 
Steven N. Singh, for the CHF-STAT Investigators. VAMC, andUniv, of 
California, San Francisco, CA 
Although amiodamne (AMIO) did not reduce total or sudden death mortality 
in the recently published CHF-STAT •al, them was a favorable trend (p = 
0.07) in patients with a non-lschemic etiology (NI) of CHR Evidence of greater 
e~icacy in NI patients has also been noted with/~.btockers in CIBtS and other 
smaller studies, and the most impressive results have been improvement in
LV function and prevention of endpoints related to progressive CHF rather 
than sudden death. Since AMIO has/~.blocking activity, the present analyses 
were undertaken to determine whether it produces similar functional and 
endpoint changes, and whether these effects occur priman'ly in Nt patients. 
in CHF-STAT, 674 patients with NYHA class 2-4 CHF (71% ischemic, 29% 
NI) and LV EF < 40% were randomized Io AMIO or placebo. At 6 rues, them 
was a greater increase in LV EF on AMIO (8.1 • 10.2 vs 2.6 ± 7.8 EF units, 
p < 0.001), but this was significantly greater in NI than CAD patients (12.3 ± 
11 vs 6,6 ± 2.1 units). The change in EF was inversely related to change in 
heart rate. An improvement inEF >_ 5% was associated with an improvement 
in survival in the N! group (p < 0.001 ), but not in CAD patients, In NI patients, 
AMIO was associated with reductions in hospitalizations for CHF (RR 0.56, 
[0,31-1.02], p = 0.06), CHF deaths plus CHF hospitalizations (RR 0.49 
[0.28-0.85], p = 0.01), and cardiac deaths plus CHF hospitalizations (RR 
0.56 [0,36-0.87], p = 0.01). None of these endpolnts was affected in CAD 
patlanta (RR 0.93-0.95). These results demonstrate that AMIO increases LV 
EF, particularly in NI caKllomyopathy. These changes am associated with 
improvement in clinical outcomes, especially those related to progressive 
CHF, in NI patients but not in those with CAD. This profile of effects is very 
similar to those observed with p-blockers in CHF. 
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~-~-~ Eflscts of Carvedilol on Cardiovascular 
Hospitalizations in Patients With Chronic Heart 
Failure 
Michael B. Fowler, E. Michael Gilbert, Jay N. Cohn, Michael A. Bristow, 
Wilson S. Colucoi, Nell H. Shusterman, Milton Packer for the Carvedilol 
Heart Failure Study Group. Stanford University, Stanford, CA 
Carvedilol (C), a nonselective /~-adrenergic blocking drug with vasodilat- 
ing and antioxidant effects was recently compared to placebo (P) in a trial 
program consisting of 4 muiticenter, andomized ouble-blind studie ~- run 
concurrently across the U.S. 1094 patients with NYHA II-IV heart failure 
(and LVEF < 35%) were randomized to receive treatment for 6-12 months. 
To evaluate the effect of C on hespifal admissions, data on art hospitatiza- 
tions were prospectively obtained throughout the study period, and analyzed 
according to protocol for patients who completed 2 months of maintenance 
therapy (588 p~ents on C, 334 on P). 
Carvediiol therapy was associated with a 38%° (95% CI: 0.149, 0.542; p = 
0.003, Cochran-ManteI.Haeeszel) reduction in risk of hospitalization (for all 
cardiovascular mesons). Hospitalization for heart failure was reduced by 47% 
(95%, Ch 0.135, 0.673; p = 0.011). Hospitalization for MI occurred in 0.3% uf 
patients randomized to C compared to 1.2% in the P group (p = 0.067). 
A decrease in the duration of the hospital stay by 1.3 days (95% CI; 0.3, 2.2; 
p = 0.009, analysis of variance) was also seen in the patients treated with C. No 
differences were observed for eardiovescular hospitalizations (CV) or hospi- 
talizations for CHF among the subgroup analyses for 1oasetine characteristics 
of age, sex, race, NYHA class, LVEF, history of MI and etiology of disease. 
In conclusio=i, earvedilot provides a substantial clinical benefit o patients 
with class II-IV heart failure by reducing the dsk of all CV hospitalizations by 
38% and hospitalizations for CHF by 473'0. The dumtlon of hospital stay was 
also shorter in patients receiving eawediloL The reduction in hospitalizations 
observed Is concordant wittt he moffality t~enefit reported in patients treated 
with ca~edHol. 
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~"5"~ Effect of Carvedilol in Severe Chronic Heart Failure 
Jay N. Cohn, Michael B. Fowler, Michael A. Bristow, Wilson S. Coluccl, E. 
Michael Gilbe¢ V'dhal Kmal, Stavan K. Kmeger, Thieny LeJemtal, Kenneth 
A. Namham, Milton Packer for the Carvedilcl Heart Failure Study Group. 
University of Minnesota, Minneapolis, MN 
Carvedilol (C), a/~.blocker with vesndilaling properties via ~l-blockade, was 
evaluated in patients with severn chronio heart faitum (CHF) [ejection fraction 
(EF) < 0.35, NYHA III/IVJ in a doubts-blind, placebo-controlled trial of 6 
months duration. The protocol was stopped eady upon recommendation of
the Data and Safety Monitoring Board to terminate Phase lit clinical •als 
in light of a survival advantage of C. Ooo-hundred live of a planned 140 
patients on standard therapy (diuretics, digoxin, and ACE-l) enJ unable to 
walk 350 rn in 6 rain were randomized to receive maximally tolerated C (n = 
70) up to 25 mg bid or placebo (P; n = 35). Parameters evaluated included 
change in quality of life (Minnesota Living with Heart Failure Questionnaire), 
patiant/physiclan global assessment and EF. Analyses (at end-paint) were 
limited to 40 patients on C and 21 on P, doe to truncation of the study. 
Results: p~Jents receiving C had a greater increase in EF at 6 months 
compared to P (+0.09 vs +0.02; p = 0.004). Ctfnical benofit was evidenced 
by improvement inthe global assessment by patients in 88% on C vs 67% 
on P (p = 0.032), and by physicians in 83%0 vs 52% (p = 0.023). Only 3% of 
pat ie~ic ians  reported worsening on C, whereas 19% patients and 15% 
physicians reported worsened CHF on R Two deaths (2.9%) occurred on C 
and two (5.7%) on R Several other measures of efficacy favored C without 
roaching statistical sk~::~noe, including change in quality of life scorn (+12 
C; +9 P), 6-rain walk distance (299.9 m on C, 278.3 m on P), improvement in
NYHA Class (23% C vs 1 9% P). Hospitalizations for worsening CHF occurred 
in 7.5% of patients on C, and 4.8% on P. 
Conclusion: The addition of ¢an~dilol to diuretics, d'rgoxin and ACE-I 
therapy in patients with severe CHF results in an improvement in EF and 
reduced risk of clinical deterioration. These data are concorda~ with the 
hamedynamic and clinical be,nef'~ observed in patients with less severn 
CHF treated with can/an31ot. 
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~- -~ '~ C arvedllol Reduces Left Ventdcular Volumes in 
Patients With Heart Failure of Ischemic Etiology 
Robert Doughty, Gillian Whalley, Stephen MacMahen, Norman Sharpe on 
behalf of the Australia-Now Zealand Heart Failure Research Collaborative 
Group. Unfversity of Auckland School of Medicine, Aucktand. New Zealand 
Bata-blocker therapy has been shown to increase left ventdoutar ejection 
